EcoDrugPlus

5-Hydroxytryptamine Receptor 2b-Like

Ensembl ID : ENSNBRG00000020740
Gene Symbol: LOC102787071
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSNBRG00000011137
Gene Symbol: HTR3A
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSNBRG00000011109
Gene Symbol: HTR3B
3 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSNBRG00000014298
Gene Symbol: HTR4
1 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a-Like

Ensembl ID : ENSNBRG00000016748
Gene Symbol: LOC102782258
3 Cross references
209 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSNBRG00000020872
Gene Symbol: HTR6
3 Cross references
114 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSNBRG00000007713
Gene Symbol: HTR7
1 Cross references
196 Possible Orthologues:

60s Acidic Ribosomal Protein P0-Like

Ensembl ID : ENSNBRG00000017013
Gene Symbol: LOC102776933
3 Cross references
398 Possible Orthologues:

60s Acidic Ribosomal Protein P1-Like

Ensembl ID : ENSNBRG00000014452
Gene Symbol: LOC102798126
3 Cross references
382 Possible Orthologues:

60s Ribosomal Protein L10-Like

Ensembl ID : ENSNBRG00000004192
Gene Symbol: LOC102791837
3 Cross references
408 Possible Orthologues:

60s Ribosomal Protein L13-Like

Ensembl ID : ENSNBRG00000011031
Gene Symbol: LOC102799254
3 Cross references
275 Possible Orthologues:

60s Ribosomal Protein L13a-Like

Ensembl ID : ENSNBRG00000024166
Gene Symbol: LOC102791818
3 Cross references
368 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).